Anxiety disorders are the most common psychiatric disorders affecting a huge population across the globe. It is a reaction to stress. Extreme level of anxiety result in anxiety disorders which include phobias, obsessive-compulsive disorder, panic disorder, post-traumatic based stress disorder. The burden of the rising prevalence of psychological conditions and the need for effective management of anxiety disorders is leading to a rise in the sales of products as well as clinical trials in the global market.
The global anxiety treatment market size is predicted to reach over USD 13.5 billion by 2028. This can be ascribed to the growing geriatric population, rising awareness about mental diseases and their treatment, and increasing number of product approvals. Besides, collaborative efforts by pharmaceutical companies, NGOs, mental health organization, and government initiatives for spreading awareness among populations are also the key factors driving the market growth for anxiety treatment.
However, patent expiry for majority of the drugs, dry pipeline for the novel drugs, mental disorders that are drug-resistant and growing numbers of different generic drugs are hampering the market growth. Furthermore, innovations and developments in herbal remedies with an improved distribution network is likely to provide lucrative development opportunities for the anxiety treatment market in the forthcoming years.
Anxiety Treatment Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 13.5 billion|
|Growth Rate||CAGR of 3.6% during 2021-2028|
|Segment Covered||Drug Class, Disorder Type, Distribution Channel, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, and Sanofi.|
Key Segments of the Global Anxiety Treatment Market
Drug Class Overview, 2019-2028 (USD Million)
- SSRIs (Selective Serotonin Reuptake Inhibitors)
- SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
- TeCAs (Tetracyclic Antidepressants) (Spool Pieces, Clamp-On, Insertion)
- TCAs (Tricyclic Antidepressants)
- MAOIs (Monoamine Oxidase inhibitors) (In-Line, Insertion, Low flow)
- Atypical Antipsychotics
Disorder Type Overview, 2019-2028 (USD Million)
- Major Depressive Disorder
Distribution Channel Overview, 2019-2028 (USD Million)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Overview, 2019-2028 (USD Million)
- Rest of Europe
- Rest of Asia-Pacific
Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- Rest of South America
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global anxiety treatment market. Benchmark yourself against the rest of the market.
- Ensure you remain competitive as innovations by existing key players to boost the market.
What does the report include?
- The study on the global anxiety treatment market includes qualitative factors such as drivers, restraints, and opportunities
- The study covers the competitive landscape of existing/prospective players in the anxiety treatment industry and their strategic initiatives for product development.
- The study covers a qualitative and quantitative analysis of the market segmented based on Drug Class, Disorder Type, and Distribution Channel. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments.
Who should buy this report?
- This study is suitable for industry participants and stakeholders in the global anxiety treatment market. The report will benefit Every stakeholder involved in the anxiety treatment market.
- Managers within the anxiety treatment industry looking to publish recent and forecasted statistics about the global anxiety treatment market.
- Government organizations, regulatory authorities, policymakers, and organizations looking for investments in trends of the global anxiety treatment market.
- Analysts, researchers, educators, strategy managers, and government institutions looking for insights into the market to determine future strategies.
Over the past few decades, the awareness about mental diseases has increased across the world, owing to the increased initiatives taken by private and public healthcare institutions. The World Health Organization (WHO) declared 10th October as the World Mental Health Day, in order to increase awareness, lessen the stigma, provide access to services, offer different treatment options, and support for mental health and related problems.
With the growing age, individuals go through a number of stress conditions. Some of which are common to all age groups, while some are old-age specific such as loss in capabilities to function properly. In addition, the elder people experience reduced socioeconomic status with retirement, which worsen the situation as it leads to isolation and loneliness. Thus, the older people are more vulnerable toward mental disorders, such as anxiety and depression. Thus, the rising cases of anxiety and depression in elderly population, across the world, would help the anxiety treatment market growth.
Furthermore, anxiety treatment is also witnessing a steady rise in the demand for the monitoring and measurement of the flow of steam, gas, water, chemicals, and mineral oil, among others. These meters offer much essential precision in terms of ideal and economic quantity during the flow measurement. They offer advantages when it comes to processing control.
The market is consolidated as several major market players currently hold the major market share. However, the market is expected to become fragmented in the forthcoming years as several new market players are emerging from developing countries such as India, Japan, China, and other countries.
Drug Class Segment
Based on the Drug Class segment, the market is bifurcated into SSRIs, SNRIs, TeCAs, TCAs, MAOIs, Atypical Antipsychotics, Benzodiazepines, Anticonvulsants and Beta-Blockers. Serotonin Norepinephrine Reuptake Inhibitors (SNRI) accumulated the maximum market share, and it is likely to continue its dominance throughout the forecast years owing to their high adoption rates. However, Selective Serotonin Reuptake Inhibitors (SSRI) drug class has the noteworthy growth throughout the forecast period. SSRIs drugs relieve symptoms of depressive disorders by blocking the reabsorption of serotonin through certain nerve cells situated in the brain. These medications are used as the first line of treatment for depression, but the remission rate associated with these drugs is higher, hence driving healthcare professionals toward alternative options that are more efficacious
Disorder Type Segment
Based on the Disorder Type, the market is segmented into Major Depressive Disorder, OCD, Phobia and PTSD. The Major Depressive Disorder segment gathered the major market share in 2020 and it is likely to continue its dominance throughout the forecast years. This growth can be attributed to the rise in number of major depressive disorder cases, coupled with growth in public awareness on this issue, and surge in frequency of screening by individuals for better mental health.
Distribution Channel Segment
Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. The Hospital Pharmacy segment gathered the major market share in 2020 and it is likely to continue its dominance throughout the forecast years owing to the increasing patients visits to look for professional help for their degrading mental health. However, the rising patient preference to buy products from nearby pharmacies on a regular basis is responsible for the growth of the retail pharmacies segment.
North America accounted for a maximum share of the global market over the forecast period owing to the rise in number of cases of pain, coupled with the greater prevalence of anxiety, growth in awareness regarding mental health, high-disposable income, in the region. Presence of major players, coupled with frequent launch of innovative products are contributing to the growth of the regional market. In addition, supportive government policies, availability of different branded formulations, and higher awareness levels are anticipated to boost the vertical growth.
However, Europe is expected to have a noteworthy growth over the forecast period owing to huge investments in R&D for the development of drugs. This, along with the higher sales of products for mental disorders is expected to drive the growth during the forecast period. In addition, improving healthcare infrastructure in emerging countries and growing awareness related to improved treatment options are the factors contributing further toward the growth of this regional segment.
The major players of the global anxiety treatment market are Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, and Sanofi. These major players in this market are focusing on increasing their presence through expansions & investments, mergers & acquisitions, partnerships, joint ventures, and agreements. Renowned companies are offering new and modern anxiety treatment. Besides, the previously recognized as well as new market players are approaching the market with advanced and new strategic services and solutions and to remain competitive in the global market.